British Columbia and Ontario recently added Rezurock® (belumosudil) to their provincial formularies for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy.1 Full reimbursement criteria are available on the British Columbia Pharmacare website and Ontario Drug Benefit website.

"People living with chronic GVHD experience serious, often multiorgan symptoms that deeply affect their everyday quality of life. Having access to Rezurock® in Quebec, and now British Columbia and Ontario will give many patients and their families renewed hope that this treatment option can help them better manage their condition, especially when symptoms are severe and previous therapies have failed."

– Dr. Michael Radford, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario

"This announcement is a significant milestone for Ontarians and British Columbians living with chronic GVHD. Public coverage makes Rezurock® accessible for patients who need this critical treatment option. We are dedicated to working with provinces and territories so that Canadians living with this serious condition can access this much-needed treatment, regardless of where they live."

– Adèle Fondeux, General Manager, General Medicines, Sanofi 

This milestone follows Quebec's coverage of Rezurock® by the Régie de l'assurance maladie du Québec (RAMQ) for this indication in November 2025. Health Canada approved Rezurock® in March 2023. Canada Drug Agency (CDA) recommended Rezurock® for reimbursement by public drug plans on March 5, 2024, specifically for patients aged 12 years and older who have been clinically diagnosed with moderate to severe chronic GVHD, whose disease has not shown an adequate response to at least two prior lines of systemic therapy.3 Full details on reimbursement criteria are available on the CDA website.